| Literature DB >> 16759978 |
Vladimír Rericha1, Michal Kulich, Robert Rericha, David L Shore, Dale P Sandler.
Abstract
OBJECTIVE: Uranium miners are chronically exposed to low levels of radon and its progeny. We investigated whether radon exposure is associated with increased incidence of leukemia, lymphoma, or multiple myeloma in this population.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16759978 PMCID: PMC1480508 DOI: 10.1289/ehp.8476
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Cohort and subcohort subjects classified by sampling strata: duration of employment and age and lifetime radon exposure by age.
| No. (%) of subjects by duration of employment
| |||||||
|---|---|---|---|---|---|---|---|
| ≥ 12 months
| < 12 months
| ||||||
| Age group | Cohort | Subcohort | Cases | Cohort | Subcohort | Cases | Mean radon |
| 19–35 | 6,857 (41.0) | 130 (7.1) | 23 (17.6) | 2,848 (45.0) | 103 (18.2) | 9 (19.6) | 5.9 |
| 36–45 | 3,336 (20.0) | 338 (18.5) | 19 (14.5) | 1,484 (23.5) | 135 (23.8) | 15 (32.6) | 37.4 |
| 46–55 | 4,057 (24.3) | 792 (43.4) | 57 (43.5) | 1,385 (21.9) | 234 (41.3) | 18 (39.1) | 78.4 |
| 56–65 | 1,756 (10.5) | 447 (24.5) | 28 (21.4) | 449 (7.1) | 74 (13.1) | 1 (2.2) | 83.0 |
| 66–90 | 715 (4.3) | 119 (6.5) | 4 (3.1) | 156 (2.5) | 21 (3.7) | 3 (6.5) | 83.7 |
| Total | 16,721 (100) | 1,826 (100) | 131 (100) | 6,322 (100) | 567 (100) | 46 (100) | 64.1 |
Age on 1 January 1977.
Mean lifetime exposure for the cases and subcohort subjects.
Incidence of diagnoses.
| Follow-up period (no. of cases)
| ||||
|---|---|---|---|---|
| Diagnosis | ICD-9 code | 1977–1996 | 1997–2001 | Total |
| Lymphosarcoma, reticulosarcoma | 200 | 11 | — | 11 |
| Hodgkin lymphoma | 201 | 23 | — | 23 |
| Non-Hodgkin lymphoma | 202 | 33 | — | 33 |
| Multiple myeloma | 203 | 26 | — | 26 |
| ALL | 204.0 | 2 | 0 | 2 |
| CLL | 204.1 | 40 | 13 | 53 |
| Aleukemic leukemia | 204.8 | 1 | 0 | 1 |
| Acute myeloid leukemia | 205.0 | 14 | 2 | 16 |
| Chronic myeloid leukemia | 205.1 | 7 | 1 | 8 |
| Other myeloid leukemia | 205.8 | 0 | 1 | 1 |
| Other leukemia | 207 | 2 | 0 | 2 |
| Unspecified leukemia | 208 | 1 | 0 | 1 |
| Total | — | 160 | 17 | 177 |
World Health Organization (1979).
Follow-up was terminated in 1996.
Numbers of cases and age-standardized incidence rates by radon exposure category.
| Radon (WLM)
| |||||||
|---|---|---|---|---|---|---|---|
| Diagnosis (ICD-9 code) | 0–5 | 5–10 | 10–25 | 25–50 | 50–100 | > 100 | Total |
| All (200–208) | |||||||
| Cases | 41 | 22 | 21 | 13 | 24 | 39 | 160 |
| O/E | 0.90 | 1.19 | 0.83 | 0.77 | 1.15 | 1.18 | |
| Rate | 32.8 | 47.8 | 33.5 | 27.7 | 39.9 | 43.3 | 39.5 |
| Hodgkin lymphoma (201) | |||||||
| Cases | 9 | 1 | 4 | 2 | 3 | 4 | 23 |
| O/E | 0.92 | 0.35 | 1.14 | 1.03 | 1.43 | 1.43 | |
| Rate | 3.3 | 1.8 | 5.4 | 3.7 | 5.7 | 3.6 | 5.0 |
| Non-Hodgkin lymphoma (200, 202) | |||||||
| Cases | 18 | 9 | 4 | 6 | 3 | 4 | 44 |
| O/E | 1.10 | 1.66 | 0.57 | 1.44 | 0.65 | 0.62 | |
| Rate | 11.7 | 16.0 | 6.0 | 10.9 | 4.6 | 7.1 | 9.4 |
| Myeloma (203) | |||||||
| Cases | 4 | 5 | 4 | 1 | 5 | 7 | 26 |
| O/E | 0.69 | 1.70 | 0.98 | 0.33 | 1.29 | 1.11 | |
| Rate | 4.7 | 11.7 | 6.7 | 2.1 | 8.1 | 6.7 | 6.7 |
| Leukemia (204–208) | |||||||
| Cases | 17 | 8 | 12 | 7 | 16 | 24 | 84 |
| O/E | 0.76 | 0.85 | 0.90 | 0.75 | 1.39 | 1.35 | |
| Rate | 13.1 | 15.3 | 15.6 | 13.6 | 24.2 | 26.7 | 17.8 |
| CLL (204.1) | |||||||
| Cases | 11 | 2 | 6 | 6 | 12 | 16 | 53 |
| O/E | 0.82 | 0.34 | 0.72 | 0.99 | 1.60 | 1.37 | |
| Rate | 9.4 | 3.9 | 7.9 | 10.5 | 18.8 | 17.4 | 11.4 |
| Myeloid leukemia (205) | |||||||
| Cases | 5 | 3 | 5 | 1 | 4 | 7 | 25 |
| O/E | 0.66 | 1.06 | 1.22 | 0.38 | 1.27 | 1.47 | |
| Rate | 3.1 | 5.8 | 6.6 | 3.1 | 5.7 | 9.0 | 5.4 |
Follow-up ended on 13 December 1996.
Observed number of cases divided by that expected under no exposure effect.
Age-standardized incidence rate per 100,000 person-years.
Including lymphosarcoma/reticulosarcoma.
Associations of radon exposure to incidence of lymphoma, myeloma, and leukemia.
| Outcome | Cases ( | RR | (95%CI) | |
|---|---|---|---|---|
| All | 160 | 1.22 | (0.87–1.72) | 0.24 |
| Hodgkin lymphoma | 23 | 2.12 | (0.81–5.52) | 0.12 |
| Non-Hodgkin lymphoma | 44 | 0.80 | (0.46–1.37) | 0.4 |
| Myeloma | 26 | 1.03 | (0.47–2.27) | 0.94 |
| Leukemia | 84 | 1.75 | (1.10–2.78) | 0.014 |
| CLL | 53 | 1.98 | (1.10–3.59) | 0.016 |
| Myeloid leukemia | 25 | 1.86 | (0.79–4.36) | 0.14 |
The reported RRs compare 110 WLM (80th percentile of the cumulative lifetime dose) to 3 WLM (20th percentile).
95% CI based on estimated parameter and SE.
p-Value for the hypothesis of no exposure effect (RR = 1) based on pseudoscore test in the power risk model.
Including lymphosarcoma/reticulosarcoma.
Figure 1Comparison of power RR and linear ERR fits based on the grouped Poisson model. The points mark empirical RRs for the exposure groups; the curves are normalized to compare exposures with the midpoint of the lowest exposure group (2.5 WLM).